DMT

DRUG3 trials

Conditions

Cognitive Function 1, SocialEmotionsEmpathyHealthyMoodMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive

Early Phase 1

Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

CompletedNCT04716335

Psychiatric University Hospital, ZurichCognitive Function 1, Social, Emotions, Empathy +1

Start: 2020-12-01End: 2022-01-10Updated: 2022-10-04

Phase 1

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

RecruitingNCT06899334

University Hospital, Basel, SwitzerlandHealthy

Start: 2025-04-01End: 2026-08-01Target: 24Updated: 2025-03-27

Unknown Phase

Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).

NCT04260711

Amsterdam UMC, location VUmcMultiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

Start: 2020-07-01End: 2024-01-01Target: 130Updated: 2020-10-19

Journal of Neurology2025-07-23

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

2025-06-07

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial

The International Journal of Neuropsychopharmacology2024-12-287 citations

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis

JAMA Neurology2024-12-0921 citations

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine

Frontiers in Pharmacology2023-11-2726 citations

DMT

Sponsors

Conditions

Early Phase 1

Phase 1

Unknown Phase

Related Papers